If you have been reading about actin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
=== Early misidentifications === Many early researchers, both before and after the periodic table was published, were eager to be the first to discover and name the missing element. Its location in the table suggested that it should be easier to find than other undiscovered elements. This turned out not to be the case, due to technetium's radioactivity.
== History == It was created by Zealand Pharma A/S of Denmark; in 2003 Zealand licensed it to Sanofi which developed the drug. Lixisenatide was approved by the European Commission in February 2013. Sanofi submitted an NDA in the US, which was accepted for review by the US FDA in February 2013, but after discussions with the FDA about the cardiovascular safety data included in the package (starting in 2008, the FDA had required stronger CV safety data for new anti-diabetes drugs, following the controversy around the risks of Avandia) Sanofi decided to withdraw the NDA and wait for the results of a Phase III study that was scheduled to be completed in 2015. Because the drug was the first GLP-1 agonist that could be taken once a day, sales projections in 2013 were €500M per year by 2018. Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. Lixisenatide received FDA approval in July 2016. In 2010, Zealand and Sanofi extended their license agreement to allow Sanofi to develop a combination therapy of lixisenatide with insulin glargine, which was Sanofi's best selling drug at the time, with sales of around €3 billion in 2009. Sanofi planned to start the Phase III trial that year. Sanofi submitted the NDA in December 2015, for the combination, called LixiLan and it was considered by the same Endocrinologic and Metabolic Drugs Advisory FDA Committee that was considering lixisenatide as a single agent.
=== Personal care and homecare === Surfactants are used in detergents, washing-up liquids, shampoos, shower gels, and similar products to increase the “solubility” of fat and dirt particles that adhere to laundry or the body in water. Fabric softeners can consist of cationic surfactants that prevent laundry from becoming stiff when dry.
Sources: en.wikipedia.org
=== Cosmetics and medicine === In nutraceutical industries, Arthrospira (Spirulina) and Chlorella are the most important species in commercialization as health foods and nutrition supplements with various health benefits including enhancing immune system activity, anti-tumor effects, and animal growth promotion, due to their abundant proteins, vitamins, active polysaccharides, and other important compounds. Microalgal carotenoids, with β-carotene from Dunaliella and astaxanthin from Haematococcus are commercially produced in large scale processes. Microalgal derived products are currently successfully developed for uses in cosmetics and pharmaceutical products. Examples include the polysaccharides from cyanobacteria used in personal skin care products and extracts of Chlorella sp. which contain oligopeptides that can promote firmness of the skin. In the pharmaceutical industries drug candidates with anti-inflammatory, anticancer, and anti-infective activities have been identified. For instance, adenosine from Phaeodactylum tricornutum, can act as an anti-arrhythmic agent for the treatment of tachycardia and the green algal metabolite caulerpin is featured in studies of anti-tuberculosis activities. Moreover, some extracellular polysaccharides from microalgae have various bioactivities involving antitumor, anti-inflammatory, and antiviral activity, providing promising prospects for pharmaceutical applications.
== Release == To promote Half-Life, Valve's chief marketing officer, Monica Harrington, promoted Valve's reputation in the industry, with conference talks about their advances in game development, leading to coverage in the Wall Street Journal. Half-Life was released on November 19, 1998. When Sierra told Valve it was not planning to promote it beyond launch, Harrington threatened that Valve would "walk away from our agreement and tell the industry that had fallen in love with Valve how screwed up Sierra really was". In response, Sierra reissued Half-Life in a "Game of the Year" edition, boosting sales. In 2001, after renegotiating with Sierra, Valve gained the Half-Life intellectual property and online distribution rights for its games. Valve released two Half-Life demos. The first, Half-Life: Day One, contained the first fifth of the game and was distributed with certain graphic cards. The second, Half-Life: Uplink, was released on February 12, 1999, and featured original content. A short film based on Half-Life, also titled Half-Life: Uplink, was developed by Cruise Control, a British marketing agency, and released on February 11. The protagonist is a journalist who infiltrates the Black Mesa Research Facility, trying to discover what has happened there. Half-Life was censored in Germany to comply with the Federal Department for Media Harmful to Young Persons, which regulates depictions of violence against humans. Valve replaced the human characters with robots, spilling oil and gears instead of blood and body parts when killed, among other changes.
While there's not much of a relationship between this hormone and physical plant behavior, there are behavioral changes that go on inside the plant in response to it. Cytokinin defense effects can include the establishment and growth of microbes (delay leaf senescence), reconfiguration of secondary metabolism or even induce the production of new organs such as galls or nodules. These organs and their corresponding processes are all used to protect the plants against biotic/abiotic factors.
Hahn spent February to June 1933 in the United States and Canada as a visiting professor at Cornell University. He gave an interview to the Toronto Star Weekly in which he painted a flattering portrait of Adolf Hitler: I am not a Nazi. But Hitler is the hope, the powerful hope, of German youth... At least 20 million people revere him. He began as a nobody, and you see what he has become in ten years.... In any case for the youth, for the nation of the future, Hitler is a hero, a Führer, a saint... In his daily life he is almost a saint. No alcohol, not even tobacco, no meat, no women. In a word: Hitler is an unequivocal Christ. The April 1933 Law for the Restoration of the Professional Civil Service banned Jews and communists from academia. Meitner was exempt from its impact because she was an Austrian rather than a German citizen. Haber was likewise exempt as a veteran of World War I, but chose to resign his directorship of the Kaiser Wilhelm Institute of Physical Chemistry and Electrochemistry in protest on 30 April 1933. The directors of the other Kaiser Wilhelm Institutes, even the Jewish ones, complied with the new law, which applied to the KWS as a whole and those Kaiser Wilhelm institutes with more than 50% state support, which exempted the KWI for Chemistry. Hahn therefore did not have to fire any of his own full-time staff, but as the interim director of Haber's institute, he dismissed a quarter of its staff, including three department heads. Gerhart Jander was appointed the new director of Haber's old institute, and reoriented it towards chemical warfare research.
Sources: en.wikipedia.org
=== Cachexia and malnutrition === Cachexia and malnutrition are related but not the same. Malnutrition happens when the body doesn't get enough nutrients, leading to changes in body weight, physical strength, and mental function. Malnutrition includes both disease-related malnutrition as well as malnutrition without disease such as seen in starvation or aging. Cachexia should be viewed as a type of malnutrition in which inflammation from a long-term illness causes unwanted muscle loss.
=== Adherence === It has been repeatedly found that in the long-term, all diets with the same calorific value perform the same for weight loss, except for the one differentiating factor of how well people can faithfully follow the dietary programme. A study comparing groups taking low-fat, low-carbohydrate and Mediterranean diets found at six months the low-carbohydrate diet still had most people adhering to it, but thereafter the situation reversed: at two years the low-carbohydrate group had the highest incidence of lapses and dropouts. This may be due to the comparatively limited food choice of low-carbohydrate diets.
=== Upper eyelid === The upper eyelid contains medial and central fat compartments and is elevated by the levator palpebrae superioris muscle. The eyelid crease is formed by attachments of the levator aponeurosis to the skin. Aging changes include excess skin and fat prominence.
Hon Lik registered a patent for the modern e-cigarette design in 2003. Hon is credited with developing the first commercially successful electronic cigarette. The e-cigarette was first introduced to the Chinese domestic market in 2004. Many versions made their way to the US, sold mostly over the Internet by small marketing firms. E-cigarettes entered the European market and the US market in 2006 and 2007. The company that Hon worked for, Golden Dragon Holdings, registered an international patent in November 2007. The company changed its name to Ruyan (如烟, literally "like smoke") later the same month, and started exporting its products. Ruyan later changed its company name to Dragonite International Limited. Many e-cigarette makers copied his designs illegally, so Hon didn't receive all of the financial reward for his invention. In 2009 his company successfully sued a competitor in China, and after getting a US patent in 2012, they launched patent infringement lawsuits against multiple US companies. In 2013 his company sold its e-vapor business to Imperial Brands for 75 million USD. As of 2014, most e-cigarettes used a battery-powered heating element rather than the earlier ultrasonic technology design. Initially, their performance did not meet the expectations of users. The e-cigarette continued to evolve from the first-generation three-part device. In 2007, British entrepreneurs Umer and Tariq Sheikh invented the cartomizer. This is a mechanism that integrates the heating coil into the liquid chamber.
==== May ==== Clashes erupted between Sweida factions, and armed groups gathered around the village of Kanaker, west of Sweida. This coincided with clashes in the towns of Ira, Rasas and al-Soura al-Kabira. The shrine and museum of Issam Zahreddine, a late Druze military officer and former commander of the Syrian Republican Guard, was vandalized and burned in al-Soura al-Kabira. General security vehicles were ambushed on 7 May by what state media called "outlaw groups" affiliated with the Suwayda Military Council. Druze leader Hikmat al-Hijri declared that "There is no consensus between us and the Damascus government". That same day, videos were released showing Burkan al-Furat, a group from Deir ez-Zor, bombing the city of Suwayda and the "al-Hijri militias" from Daraa Governorate. According to activist Samer Salloum, it was the Syrian transitional government that allowed entry into the south. On 21 May 2025, an armed group, "led by Fadi Nasr, with support from Tariq al-Nagoush", took Mustafa al-Bakour, the governor of Suwayda governorate, hostage at the town hall, demanding and securing the release of Raghib Qarqout, who is a convicted car thief. The Men of Dignity movement was mobilised and secured the governor's exit route from the building, while the Al-Jabal Brigade engaged with the gunmen. Al-Bakour submitted his resignation two days later. On 22 May, the Islamic State claimed attacks in Al-Safa, in Suwayda Governorate, against the Ministry of Defense, being the first attack by the Islamic State against the Syrian transitional government, since the Fall of Assad.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.